GlassScriptPhysician profile
Daniel M Marion
NPI 1275875908
$14,517.10
in general payments reported to CMS, 2019-2025
46 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $1,672 · 2021: $2,090 · 2022: $1,800 · 2023: $2,397 · 2024: $2,190 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,998 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,998.04 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,692.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,550.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,409.14 | 2021-2025 | |
| Lilly USA, LLC | $1,128.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,015.80 | 2019-2025 | |
| Novo Nordisk INC | $1,014.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $537.57 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $522.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $519.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.32 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $424.37 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.97 | 2019-2025 | Xifaxan, Ibschek |
| Astellas Pharma US INC | $404.96 | 2019-2023 | Myrbetriq, Veozah |
| Esperion Therapeutics, INC. | $385.93 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $328.23 | 2021-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.